Cancer News and Research

Latest Cancer News and Research

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.

2 Jun 2010

New report shows one in three young women receive HPV vaccine to prevent cervical cancer

Only about one in three young women has received the human papillomavirus vaccine to help prevent cervical cancer, according to a new report from researchers at Washington University School of Medicine in St. Louis.

2 Jun 2010

Cancer patients should find ways to be physically active during and after treatment: New national guidelines

Cancer patients who've been told to rest and avoid exercise can - and should - find ways to be physically active both during and after treatment, according to new national guidelines. Kathryn Schmitz, PhD, MPH, an associate professor of Epidemiology and Biostatistics and a member of the Abramson Cancer Center at the University of Pennsylvania School of Medicine, will present these guidelines at an educational session at the 2010 meeting of the American Society of Clinical Oncology, aimed at making cancer exercise rehabilitation programs as common as those offered to people who have had heart attacks or undergone cardiac surgery.

2 Jun 2010

Scientists discover key mechanism of cancer cells

Many tumor cells would not be viable due to aberrant chromosome distribution if they had not developed a special trick. Scientists from the German Cancer Research Center have investigated which genes are responsible for this survival strategy of cancer cells.

2 Jun 2010

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Onyx Pharmaceuticals, Inc. today announced the initiation of a Phase 1 study of ONX 0912, an oral proteasome inhibitor, in patients with advanced refractory or recurrent solid tumors.

2 Jun 2010

Study sheds light on molecular mechanisms of genital and urinary tract abnormalities

Scientists have learned how a gene widely known for precisely positioning and sculpting various organs also controls the speed of cell division, a finding that could be useful for understanding the explosive growth of cancer cells or why increasing numbers of children are being born with genital and urinary tract malformations.

2 Jun 2010

Postdoctoral scientists receive NYSCF-Druckenmiller Fellowship award

The New York Stem Cell Foundation (NYSCF) today announced the award of eight new NYSCF-Druckenmiller Fellows. These postdoctoral scientists join 15 accomplished stem cell researchers from leading institutions who have been supported by the program since 2006. NYSCF has awarded 23 fellowships to date.

2 Jun 2010

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.

2 Jun 2010

New model reveals molecular basis of multiple hereditary exostoses

Children born with multiple hereditary exostoses (MHE) suffer from abnormal growths on their bones. These bony protrusions stunt their growth and can cause pain and disfigurement.

2 Jun 2010

Study results show calcium consumption increases prostate cancer risk in Chinese

Among Chinese men, calcium consumption — even at relatively low levels and from non-dairy food sources such as soy, grains and green vegetables — may increase prostate cancer risk, according to results published in Cancer Research, a journal of the American Association for Cancer Research.

2 Jun 2010

DARA BioSciences regains compliance with NASDAQ minimum bid price requirement

DARA BioSciences, Inc. today announced that, on May 28 2010, NASDAQ notified the Company that it has regained compliance with the minimum bid price requirement as set forth in NASDAQ Listing Rule 5550(a)(2). On May 26, 2010, the Company's closing bid price was $3.58 per share, the tenth consecutive day it had been above $1 per share.

2 Jun 2010

Businesses fret penalties, seek opportunities in health overhaul

Some small businesses may get financial help as part of the health overhaul that could cover up to 35 percent of business's premium costs for insuring employees in the form of new tax credits, Kaiser Health News explains in a consumer column.

2 Jun 2010

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.

2 Jun 2010

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

CoaguSense™, Inc., a diagnostic device company that has been in stealth mode for the past two years, today unveiled the first portable point-of-care Prothrombin Time/International Normalized Ratio (PT/INR) analyzer to directly detect blood clotting time for patients stabilized on oral anti-coagulation medications such as Coumadin® or warfarin.

2 Jun 2010

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

Findings from a new study show that more and more Australians are being diagnosed with bowel cancer and costs of treatment may well touch $1 billion next year a sharp rise from the $235 million in 2001. The study says that there are more than 13,500 Australians diagnosed with bowel cancer each year.

1 Jun 2010

New technique transforms iPS cells into natural tumor killers

A technique for producing natural killer T (NKT) cells, known for their role in suppressing tumor growth, has been successfully demonstrated for the first time using induced pluripotent stem (iPS) cells. Developed by researchers at RIKEN, Japan’s flagship research institution, the technique opens the door to effective new cell-targeted treatments for cancer.

1 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Oncolytics Biotech Inc. today announced that it has received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

1 Jun 2010

Europe spends just 5% of total cancer research funds on metastases

On average, about five percent of total cancer research funding is spent on investigating metastases (the spread of cancer cells around the body) in Europe, yet metastatic disease is the direct or indirect cause of 90 percent of all cancer deaths, according to an editorial in the European Journal of Cancer (EJC).

1 Jun 2010

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.

1 Jun 2010

Cancer News and Research

Latest Cancer News and Research

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

New report shows one in three young women receive HPV vaccine to prevent cervical cancer

Cancer patients should find ways to be physically active during and after treatment: New national guidelines

Scientists discover key mechanism of cancer cells

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Study sheds light on molecular mechanisms of genital and urinary tract abnormalities

Postdoctoral scientists receive NYSCF-Druckenmiller Fellowship award

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

New model reveals molecular basis of multiple hereditary exostoses

Study results show calcium consumption increases prostate cancer risk in Chinese

DARA BioSciences regains compliance with NASDAQ minimum bid price requirement

Businesses fret penalties, seek opportunities in health overhaul

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

New technique transforms iPS cells into natural tumor killers

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Europe spends just 5% of total cancer research funds on metastases

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

Understanding the DNA Damage Response in Innate Immunity eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Newsletters you may be interested in